查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球智慧藥丸市場按治療領域、應用、適應症、最終用戶和地區分類 - 預測至 2030 年
市場調查報告書
商品編碼
1695352

全球智慧藥丸市場按治療領域、應用、適應症、最終用戶和地區分類 - 預測至 2030 年

Smart Pills Market by Application (Capsule Endoscopy, Drug Delivery, Patient Monitoring), Target Area (Esophagus, Small Intestine, Large Intestine, Stomach), End User (Hospitals, Diagnostic Centers), and Region - Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 230 Pages | 訂單完成後即時交付

價格

受膠囊內視鏡技術進步和非侵入性診斷監測設備需求不斷成長的推動，全球智慧藥丸市場規模預計將在 2024 年實現顯著成長。

預計將從 2024 年的 6.9 億美元成長到 2030 年的 13 億美元，預測期內的複合年成長率為 11.2%。根據美國癌症協會（ACS）的數據，2024年將有152,810例新發大腸直腸癌（CRC）病例，其中男性81,540例，女性71,270例。此外，結腸癌病例為106,590例，直腸癌病例為46,220例。 CRC 仍然是美國癌症死亡的第二大原因，預計 2024 年死亡人數將達到 53,010 人，略高於去年的 52,550 人。因此，結腸癌的高發性預計將增加對結腸癌篩檢的膠囊內視鏡的需求。

研究範圍
調查年份 2023-2030
基準年 2023
預測期 2023-2030
考慮單位 金額（十億美元）
按細分市場 按治療領域、按應用、按疾病適應症、按最終用戶、按地區
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東和非洲

根據適應症，智慧藥丸市場分為克隆氏症、小腸腫瘤、隱匿性胃腸道出血、乳糜瀉和其他適應症。預計在預測期內，小腸腫瘤將以最高的複合年成長率成長，這得益於感測器技術的進步、對患者便利性的日益關注以及對腫瘤早期診斷和適當治療的需求不斷成長等因素，預計這些因素將推動未來幾年智慧藥丸的普及。

智慧藥丸市場根據目標區域大致分為小腸、大腸、食道和胃。 2023年，大腸直腸癌將佔據智慧藥丸市場第二大佔有率。這些因素包括大腸直腸癌患者數量的增加，以及對發炎性腸道疾病腸道疾病和其他消化系統疾病的篩檢、診斷和檢測應用的需求。隨著大腸直腸癌和結腸癌病例的增加，大腸智慧藥丸的採用正在增加，因為智慧藥丸可以到達傳統方法難以觀察到的大腸區域。

2023 年，歐洲將佔據智慧藥丸市場的第二大佔有率。人口老化和膠囊內視鏡在胃腸道 (GI) 出血方面的使用增加等因素正在推動歐洲智慧藥丸市場的發展。根據歐洲胃腸內視鏡學會（ESGE）指南，建議小腸視訊膠囊內視鏡檢查作為不明原因消化道出血患者的初步檢查。 ESGE 指南對膠囊內視鏡檢查的建議為醫療保健專業人員提供了統一的方法，並提高了患者的護理品質。因此，隨著膠囊內視鏡在消化道出血中的應用越來越廣泛，對智慧藥丸和其他相關技術的需求也日益成長。

本報告研究了全球智慧藥丸市場，並按治療領域、應用、適應症、最終用戶、區域趨勢和公司概況對市場進行了詳細分析。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章 市場概況

  • 介紹
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
    • 任務
  • 產業趨勢
    • 感測器技術的進步
    • 人工智慧和機器學習整合
    • 與穿戴式裝置整合
  • 技術分析
  • 影響客戶業務的趨勢/干擾
  • 管道分析
  • 波特五力分析
  • 主要相關人員和採購標準
  • 生態系分析
  • 價值鏈分析
  • 資費與監理分析
  • 定價分析
  • 案例研究分析
  • 專利分析
  • 2025-2026 年重要會議與活動
  • 未滿足的需求和最終用戶的期望
  • 貿易分析
  • 投資金籌措場景
  • 經營模式分析
  • 人工智慧/生成式人工智慧對智慧藥丸市場的影響

第6章 智慧藥丸市場（依治療領域分類）

  • 介紹
  • 小腸
  • 冒號
  • 食道
  • 胃

第 7 章 智慧藥丸市場（按應用）

  • 介紹
  • 膠囊內視鏡
  • 病患監護
  • 靶向藥物輸送

第 8 章 智慧藥丸市場（依適應症分類）

  • 介紹
  • 隱匿性消化道出血
  • 克隆氏症
  • 乳糜瀉
  • 小腸腫瘤
  • 其他

第 9 章 智慧藥丸市場（按最終用戶分類）

  • 介紹
  • 醫院
  • 診斷中心
  • 門診護理
  • 其他

第 10 章 智慧藥丸市場（按地區）

  • 介紹
  • 北美洲
    • 北美宏觀經濟展望
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲宏觀經濟展望
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 亞太宏觀經濟展望
    • 日本
    • 中國
    • 印度
    • 其他
  • 拉丁美洲
    • 拉丁美洲宏觀經濟展望
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 中東和非洲宏觀經濟展望
    • 海灣合作理事會國家
    • 其他

第11章 競爭格局

  • 介紹
  • 主要參與企業的策略/優勢
  • 2019 至 2023 年收益分析
  • 2023 年市場佔有率分析
  • 公司估值矩陣：主要參與企業，2023 年
  • 公司估值矩陣：Start-Ups/中小企業，2023 年
  • 估值及財務指標
  • 品牌/產品比較
  • 競爭場景

第12章 公司簡介

  • 主要參與企業
    • MEDTRONIC
    • OLYMPUS CORPORATION
    • CAPSOVISION, INC.
    • INTROMEDIC
    • JINSHAN SCIENCE & TECHNOLOGY
    • ANX ROBOTICS
    • SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.
    • ETECTRX
    • BODYCAP
    • CHECK-CAP
    • SHANGXIAN MINIMAL INVASIVE INC.
  • 其他公司
    • VELOCE CORPORATION
    • BIOCAM
    • ENDIATX
    • RF CO., LTD.
    • CELERO SYSTEMS
    • BIORA THERAPEUTICS, INC.
    • INNURVATION
    • RANI THERAPEUTICS
    • MOTILIS MEDICA SA

第13章 附錄

Product Code: MD 3264

The global smart pills market is experiencing significant growth in 2024, driven by the technological advancements in capsule endoscopy and the growing demand for non-invasive diagnostic monitoring devices. The market is projected to reach reach USD 1.30 billion by 2030 from USD 0.69 billion in 2024, at a CAGR of 11.2% during the forecast period. According to the American Cancer Society (ACS), in 2024, there were 1,52,810 new cases of colorectal cancer (CRC) comprising, 81,540 will be in men and 71,270 in women. Additionally, 1,06,590 of the cases will be colon cancer, while 46,220 will be rectal cancer. CRC remains the second leading cause of cancer-related deaths in the US with an estimated 53,010 deaths in 2024, showing a slight increase from last year's projected 52,550. Thus, the high incidence of colon cancer are expected to increase the demand for capsule endoscopes for colon cancer screening.

Scope of the Report
Years Considered for the Study2023-2030
Base Year2023
Forecast Period2023-2030
Units ConsideredValue (USD billion)
SegmentsBy Application, Target Area, Disease Indication, End User & Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East & Africa

"The small bowel tumor segment is projected to grow at the highest CAGR during the forecast period."

Based on disease indication, the market for smart pills is divided into segments for crohn's disease, small bowel tumors, occult GI bleeding, celiac disease, and other disease indications. The small bowel tumor is expected to grow at the highest CAGR during the forecast period due to factors, such as advancements in sensor technology, growing emphasis on patient convenience, rising need for early tumor diagnosis and proper treatment that are expected to drive the adoption of smart pills in the coming years.

"The large intestine accounted for the second largest share of the market during the forecast period in 2023, by target area. "

By target area, the smart pills market is broadly segmented into, small intestine, large intestine, esophagus, and stomach. In 2023, the large intestine target area accounted for the second largest share of smart pills market. Factors such as rising cases of colorectal cancer and requirement for applicable screening, diagnosis, and examining of inflammatory bowel diseases and other gastrointestinal diseases. The growing cases of colorectal cancer & colon cancer have contributed to the rising adoption of smart pills in large intestine as smart pills can reach areas of the colon that may be difficult to visualize with traditional methods.

By region, Europe hold the second largest share of the smart pills market in 2023

Europe accounted for the second largest share of the smart pills market in 2023. Factors such as increase in ageing population and improved utilization of capsule endoscopy for gastrointestinal (GI) bleeding are driving the European smart pills market. According to the guidelines of the European Society of Gastrointestinal Endoscopy (ESGE), small-bowel video capsule endoscopy is recommended as the initial examination for patients with unclear gastrointestinal bleeding. The endorsement of capsule endoscopy by the ESGE guidelines specifies a uniform approach for healthcare professionals, improving the quality of care provided to patients. As a result, the expanding demand for smart pills and other related technologies is driven by the growing use of capsule endoscopy for GI bleeding.

The break up of the profile of primary participants in the smart pills market:

  • By Company Type: Tier 1- 40%, Tier 2- 35%, and Tier 25%
  • By Designation: C-level Executives- 50%, Directors- 40% , and Others- 10%.
  • By Region: North America- 45%, Europe- 30%, Asia Pacific- 20%, Latin America- 3%, and Middle East & Africa- 2%.

Key players in the Smart pills market

The key players operating in the smart pills market include Medtronic (US), Olympus Corporation (Japan), CapsoVision,Inc. (US), IntroMedic (South Korea), ANX Robotics (US), Shenzhen Jifu Medical Technology Co., Ltd. (China), JINSHAN Science & Technology (Group) (China), etectrx (US), Check-Cap (Israel), BodyCap (France) ,and Shangxian Minimal Invasive Inc (China).

Research Coverage:

The report analyzes the smart pills market and aims at estimating the market size and future growth potential of this market based on various segments such as application (capsule endoscopy,patient monitoring, and targeted drug delivery), target area (small intestine,large intestine, esophagus & stomach), disease indication (crohn's disease, occult GI bleeding, small bowel tumor, celiac disease, & other disease conditions), end user (hospitals, diagnostic centers, outpatient settings, & other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa). The report also includes a product portfolio matrix of various smart pills products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, service offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

  • Analysis of key drivers (rising demand for noninvasive diagnostic monitoring devices, technological advancements in capsule endoscopy, increasing incidence of colon cancer), restraints (high costs & technical limitations associated with accuracy of smart pills), opportunities (continuous innovation in sensor technology, wireless communication and rising need for rapid drug delivery development) and challenges (patient privacy concerns, shortage of skilled personnel).
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the smart pills market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the smart pills market across varied regions.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the smart pills market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of Medtronic (US), Olympus Corporation (Japan), CapsoVision,Inc. (US), IntroMedic (South Korea), ANX Robotics (US), Shenzhen jifu Medical Technology Co., Ltd. (China), JINSHAN Science & Technology (Group) (China), etectrx (US), Check-Cap (Israel), BodyCap (France) , and Shangxian Minimal Invasive Inc (China) in the smart pills market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION & GEOGRAPHICAL SPREAD
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key sources of secondary data
      • 2.1.1.2 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Objectives of primary research
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Insights from primary experts
    • 2.1.3 MARKET SIZE ESTIMATION
      • 2.1.3.1 Supply-side analysis
      • 2.1.3.2 Bottom-up approach (demand-side analysis)
      • 2.1.3.3 Top-down approach (parent market assessment)
  • 2.2 DATA TRIANGULATION
  • 2.3 STUDY ASSUMPTIONS
  • 2.4 RISK ANALYSIS
  • 2.5 RESEARCH LIMITATIONS
    • 2.5.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.5.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 SMART PILLS MARKET OVERVIEW
  • 4.2 NORTH AMERICA: SMART PILLS MARKET, BY APPLICATION AND COUNTRY, 2023
  • 4.3 SMART PILLS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4 SMART PILLS MARKET: REGIONAL MIX
  • 4.5 SMART PILLS MARKET: DEVELOPED VS. EMERGING MARKETS

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising demand for non-invasive diagnostic monitoring devices
      • 5.2.1.2 Technological advancements in capsule endoscopy
      • 5.2.1.3 Increasing incidence of colon cancer
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High R&D costs for technological developments and advancements
      • 5.2.2.2 Low accuracy and reliability of sensors and cameras in smart pills
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Innovations in sensor technologies and wireless communication
      • 5.2.3.2 Rising need for rapid drug delivery and development
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Increased patient privacy and data security concerns
      • 5.2.4.2 Shortage of skilled healthcare professionals
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 ADVANCEMENTS IN SENSOR TECHNOLOGIES
    • 5.3.2 INTEGRATION WITH AI AND ML
    • 5.3.3 INTEGRATION WITH WEARABLE DEVICES
  • 5.4 TECHNOLOGY ANALYSIS
    • 5.4.1 KEY TECHNOLOGIES
      • 5.4.1.1 Wireless communication systems
      • 5.4.1.2 Sensor technologies
      • 5.4.1.3 Self-powered ingestible smart pills
      • 5.4.1.4 Adaptive frame rate technologies
      • 5.4.1.5 iMAG
      • 5.4.1.6 AI and ML
    • 5.4.2 COMPLEMENTARY TECHNOLOGIES
      • 5.4.2.1 Robotic technologies
      • 5.4.2.2 Data analytics
    • 5.4.3 ADJACENT TECHNOLOGIES
      • 5.4.3.1 IoT
      • 5.4.3.2 Cloud computing
  • 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
  • 5.6 PIPELINE ANALYSIS
  • 5.7 PORTER'S FIVE FORCES ANALYSIS
    • 5.7.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.7.2 THREAT OF NEW ENTRANTS
    • 5.7.3 THREAT OF SUBSTITUTES
    • 5.7.4 BARGAINING POWER OF SUPPLIERS
    • 5.7.5 BARGAINING POWER OF BUYERS
  • 5.8 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.8.2 KEY BUYING CRITERIA
  • 5.9 ECOSYSTEM ANALYSIS
  • 5.10 VALUE CHAIN ANALYSIS
  • 5.11 TARIFF & REGULATORY ANALYSIS
    • 5.11.1 TARIFF DATA ANALYSIS
    • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.11.3 REGULATORY LANDSCAPE
      • 5.11.3.1 North America
        • 5.11.3.1.1 US
      • 5.11.3.2 Europe
      • 5.11.3.3 Asia Pacific
        • 5.11.3.3.1 Japan
        • 5.11.3.3.2 China
        • 5.11.3.3.3 India
  • 5.12 PRICING ANALYSIS
    • 5.12.1 AVERAGE SELLING PRICE OF SMART PILLS, BY KEY PLAYER, 2023
    • 5.12.2 AVERAGE SELLING PRICE TREND FOR CAPSULE ENDOSCOPES, BY REGION, 2020-2023
  • 5.13 CASE STUDY ANALYSIS
    • 5.13.1 INCREASED IMAGING CAPABILITIES FOR PATIENTS WITH SMALL BOWEL ABNORMALITIES
    • 5.13.2 DETECTION OF GASTRIC POLYP & ERYTHEMA THROUGH MAGNETICALLY CONTROLLED CAPSULE ENDOSCOPES
    • 5.13.3 AI-ASSISTED CAPSULE ENDOSCOPY TO DETECT OBSCURE GASTROINTESTINAL BLEEDING IN HIGH-RISK CARDIAC PATIENTS
  • 5.14 PATENT ANALYSIS
    • 5.14.1 PATENT PUBLICATION TRENDS FOR SMART PILLS
    • 5.14.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
    • 5.14.3 LIST OF KEY PATENTS
  • 5.15 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.16 UNMET NEEDS & END-USER EXPECTATIONS
    • 5.16.1 UNMET NEEDS
    • 5.16.2 END-USER EXPECTATIONS
  • 5.17 TRADE ANALYSIS
  • 5.18 INVESTMENT & FUNDING SCENARIO
  • 5.19 BUSINESS MODEL ANALYSIS
    • 5.19.1 DIRECT SALES TO HEALTHCARE PROVIDERS
    • 5.19.2 SUBSCRIPTION-BASED SOFTWARE AND DATA ANALYTICS SERVICES
  • 5.20 IMPACT OF AI/GEN AI ON SMART PILLS MARKET
    • 5.20.1 KEY USE CASES
    • 5.20.2 CASE STUDIES OF AI/GEN AI IMPLEMENTATION
      • 5.20.2.1 CapsoCam SV-1 Versus PillCam SB3 to detect obscure gastrointestinal bleeding
      • 5.20.2.2 AARDEX Group partnered with etectRx, Inc. to track medication-taking behaviors
    • 5.20.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
      • 5.20.3.1 AI in endoscopy
      • 5.20.3.2 Wearable devices
      • 5.20.3.3 Digital healthcare
      • 5.20.3.4 Home healthcare
    • 5.20.4 USER READINESS & IMPACT ASSESSMENT
      • 5.20.4.1 User readiness
        • 5.20.4.1.1 User A: Hospitals
        • 5.20.4.1.2 User B: Diagnostic centers
      • 5.20.4.2 Impact assessment
        • 5.20.4.2.1 User A: Hospitals
          • 5.20.4.2.1.1 Implementation
          • 5.20.4.2.1.2 Impact
        • 5.20.4.2.2 User B: Diagnostic centers
          • 5.20.4.2.2.1 Implementation
          • 5.20.4.2.2.2 Impact

6 SMART PILLS MARKET, BY TARGET AREA

  • 6.1 INTRODUCTION
  • 6.2 SMALL INTESTINE
    • 6.2.1 COMPLEXITIES IN DIAGNOSIS AND MONITORING OF SMALL INTESTINE TO AID ADOPTION OF SMART PILLS
  • 6.3 LARGE INTESTINE
    • 6.3.1 INCREASING INCIDENCE OF COLORECTAL CANCER TO SUPPORT MARKET GROWTH
  • 6.4 ESOPHAGUS
    • 6.4.1 HIGH PREVALENCE OF GASTROESOPHAGEAL REFLUX DISEASE AND BARRETT'S ESOPHAGUS TO AUGMENT MARKET GROWTH
  • 6.5 STOMACH
    • 6.5.1 IMPROVED DIAGNOSTIC ACCURACY AND EFFECTIVE PROXIMAL EXAMINATION SCOPE OF GASTRIC DISEASES TO DRIVE MARKET

7 SMART PILLS MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
  • 7.2 CAPSULE ENDOSCOPY
    • 7.2.1 INCREASED ABILITY TO ASSESS GASTROINTESTINAL BLEEDING AND SMALL BOWEL TUMORS TO DRIVE MARKET
  • 7.3 PATIENT MONITORING
    • 7.3.1 NEED FOR STREAMLINED INTEGRATION OF INNOVATIVE SENSOR TECHNOLOGIES TO DRIVE MARKET
  • 7.4 TARGETED DRUG DELIVERY
    • 7.4.1 SITE-SPECIFIC DRUG DELIVERY TO MINIMIZE DRUG DOSAGE AND REDUCE HEALTHCARE COSTS

8 SMART PILLS MARKET, BY DISEASE INDICATION

  • 8.1 INTRODUCTION
  • 8.2 OCCULT GASTROINTESTINAL BLEEDING
    • 8.2.1 IMPROVED DIAGNOSTIC ACCURACY TO FUEL UPTAKE OF SMART PILLS AS PATIENT-FRIENDLY ALTERNATIVE
  • 8.3 CROHN'S DISEASE
    • 8.3.1 TECHNOLOGICAL ADVANCEMENTS IN CAPSULE ENDOSCOPY TO BOOST ADOPTION OF SMART PILLS
  • 8.4 CELIAC DISEASE
    • 8.4.1 RISING INCIDENCE OF SMALL INTESTINE DISORDERS TO DRIVE MARKET
  • 8.5 SMALL BOWEL TUMORS
    • 8.5.1 GROWING DEMAND FOR NON-INVASIVE DIAGNOSTICS TO PROPEL MARKET GROWTH
  • 8.6 OTHER DISEASE INDICATIONS

9 SMART PILLS MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 HOSPITALS
    • 9.2.1 INCREASING PREVALENCE OF INFLAMMATORY BOWEL DISEASE TO BOOST ADOPTION OF SMART PILLS IN HOSPITALS
  • 9.3 DIAGNOSTIC CENTERS
    • 9.3.1 BETTER PATIENT EXPERIENCE AND IMPROVED OPERATIONAL EFFICIENCY TO BOOST MARKET GROWTH
  • 9.4 OUTPATIENT SETTINGS
    • 9.4.1 NEED FOR ACCESSIBLE AND COST-EFFECTIVE CARE TO SPUR MARKET GROWTH
  • 9.5 OTHER END USERS

10 SMART PILLS MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 10.2.2 US
      • 10.2.2.1 US to dominate North American smart pills market during study period
    • 10.2.3 CANADA
      • 10.2.3.1 Rising incidence of IBD among geriatric population to propel market growth
  • 10.3 EUROPE
    • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 10.3.2 GERMANY
      • 10.3.2.1 Rising prevalence of Crohn's disease to aid market growth
    • 10.3.3 UK
      • 10.3.3.1 Increasing prevalence of bowel cancer and colitis to augment market growth
    • 10.3.4 FRANCE
      • 10.3.4.1 Favorable reimbursement coverage by government and third-party payers to aid market growth
    • 10.3.5 ITALY
      • 10.3.5.1 Growing adoption of capsule endoscopy for gastrointestinal diseases to propel market growth
    • 10.3.6 SPAIN
      • 10.3.6.1 Rising demand for non-invasive diagnostics to fuel uptake of smart pills
    • 10.3.7 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 10.4.2 JAPAN
      • 10.4.2.1 Increased prevalence of stomach cancer and favorable reimbursement scenario for capsule endoscopy to drive market
    • 10.4.3 CHINA
      • 10.4.3.1 Increasing geriatric population and rising incidence of gastric cancer to boost market growth
    • 10.4.4 INDIA
      • 10.4.4.1 Rising incidence of IBD and growing adoption of capsule endoscopy to support market growth
    • 10.4.5 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 10.5.2 BRAZIL
      • 10.5.2.1 Favorable government policies and presence of universal health coverage to aid market growth
    • 10.5.3 MEXICO
      • 10.5.3.1 Increased cancer awareness and favorable government initiatives to drive market
    • 10.5.4 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 10.6.2 GCC COUNTRIES
      • 10.6.2.1 Increased focus on healthcare infrastructure development and high R&D investment to support market growth
    • 10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SMART PILLS MARKET
  • 11.3 REVENUE ANALYSIS, 2019-2023
  • 11.4 MARKET SHARE ANALYSIS, 2023
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 11.5.5.1 Company footprint
      • 11.5.5.2 Region footprint
      • 11.5.5.3 Application footprint
      • 11.5.5.4 Target area footprint
      • 11.5.5.5 Disease indication footprint
      • 11.5.5.6 End-user footprint
      • 11.5.5.7 Region footprint
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 STARTING BLOCKS
    • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
      • 11.6.5.1 Detailed list of key startups/SME players
      • 11.6.5.2 Competitive benchmarking of key startups/SME players
  • 11.7 COMPANY VALUATION & FINANCIAL METRICS
    • 11.7.1 FINANCIAL METRICS
    • 11.7.2 COMPANY VALUATION
  • 11.8 BRAND/PRODUCT COMPARISON
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS
    • 11.9.2 DEALS
    • 11.9.3 OTHER DEVELOPMENTS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
    • 12.1.1 MEDTRONIC
      • 12.1.1.1 Business overview
      • 12.1.1.2 Products/Services/Solutions offered
      • 12.1.1.3 Recent developments
        • 12.1.1.3.1 Product approvals & enhancements
        • 12.1.1.3.2 Deals
      • 12.1.1.4 MnM view
        • 12.1.1.4.1 Right to win
        • 12.1.1.4.2 Strategic choices
        • 12.1.1.4.3 Weaknesses & competitive threats
    • 12.1.2 OLYMPUS CORPORATION
      • 12.1.2.1 Business overview
      • 12.1.2.2 Products/Services/Solutions offered
      • 12.1.2.3 Recent developments
        • 12.1.2.3.1 Other developments
      • 12.1.2.4 MnM view
        • 12.1.2.4.1 Right to win
        • 12.1.2.4.2 Strategic choices
        • 12.1.2.4.3 Weaknesses & competitive threats
    • 12.1.3 CAPSOVISION, INC.
      • 12.1.3.1 Business overview
      • 12.1.3.2 Products/Services/Solutions offered
      • 12.1.3.3 Recent developments
        • 12.1.3.3.1 Product approvals & enhancements
      • 12.1.3.4 MnM view
        • 12.1.3.4.1 Right to win
        • 12.1.3.4.2 Strategic choices
        • 12.1.3.4.3 Weaknesses & competitive threats
    • 12.1.4 INTROMEDIC
      • 12.1.4.1 Business overview
      • 12.1.4.2 Products/Services/Solutions offered
      • 12.1.4.3 MnM view
        • 12.1.4.3.1 Right to win
        • 12.1.4.3.2 Strategic choices
        • 12.1.4.3.3 Weaknesses & competitive threats
    • 12.1.5 JINSHAN SCIENCE & TECHNOLOGY
      • 12.1.5.1 Business overview
      • 12.1.5.2 Products/Services/Solutions offered
      • 12.1.5.3 MnM view
        • 12.1.5.3.1 Right to win
        • 12.1.5.3.2 Strategic choices
        • 12.1.5.3.3 Weaknesses & competitive threats
    • 12.1.6 ANX ROBOTICS
      • 12.1.6.1 Business overview
      • 12.1.6.2 Products/Services/Solutions offered
      • 12.1.6.3 Recent developments
        • 12.1.6.3.1 Product launches, approvals, and enhancements
    • 12.1.7 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.
      • 12.1.7.1 Business overview
      • 12.1.7.2 Products/Services/Solutions offered
    • 12.1.8 ETECTRX
      • 12.1.8.1 Business overview
      • 12.1.8.2 Products/Services/Solutions offered
      • 12.1.8.3 Recent developments
        • 12.1.8.3.1 Product enhancements
        • 12.1.8.3.2 Deals
    • 12.1.9 BODYCAP
      • 12.1.9.1 Business overview
      • 12.1.9.2 Products/Services/Solutions offered
      • 12.1.9.3 Recent developments
        • 12.1.9.3.1 Product launches
        • 12.1.9.3.2 Deals
    • 12.1.10 CHECK-CAP
      • 12.1.10.1 Business overview
      • 12.1.10.2 Products/Services/Solutions offered
      • 12.1.10.3 Recent developments
        • 12.1.10.3.1 Product approvals
        • 12.1.10.3.2 Expansions
    • 12.1.11 SHANGXIAN MINIMAL INVASIVE INC.
      • 12.1.11.1 Business overview
      • 12.1.11.2 Products/Services/Solutions offered
  • 12.2 OTHER PLAYERS
    • 12.2.1 VELOCE CORPORATION
    • 12.2.2 BIOCAM
    • 12.2.3 ENDIATX
    • 12.2.4 RF CO., LTD.
    • 12.2.5 CELERO SYSTEMS
    • 12.2.6 BIORA THERAPEUTICS, INC.
    • 12.2.7 INNURVATION
    • 12.2.8 RANI THERAPEUTICS
    • 12.2.9 MOTILIS MEDICA SA

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 SMART PILLS MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 SMART PILLS MARKET: STUDY ASSUMPTIONS
  • TABLE 3 SMART PILLS MARKET: RISK ANALYSIS
  • TABLE 4 SMART PILLS MARKET: IMPACT ANALYSIS
  • TABLE 5 SENSOR AND BATTERY TYPES FOR CAPSULE ENDOSCOPY PRODUCTS
  • TABLE 6 SENSORS USED FOR VITAL SIGN MONITORING PRODUCTS
  • TABLE 7 SMART PILLS MARKET: DRUGS UNDER PIPELINE
  • TABLE 8 SMART PILLS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 9 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY APPLICATION (%)
  • TABLE 10 KEY BUYING CRITERIA FOR SMART PILLS, BY APPLICATION
  • TABLE 11 TARIFF DATA FOR HS CODE 901890
  • TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 US FDA: MEDICAL DEVICE CLASSIFICATION
  • TABLE 16 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 17 EUROPE: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 18 JAPAN: MEDICAL DEVICES CLASSIFICATION UNDER PMDA
  • TABLE 19 CHINA: CLASSIFICATION UNDER CLASS I/II/III MEDICAL DEVICES
  • TABLE 20 INDIA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 21 AVERAGE SELLING PRICE OF CAPSULE ENDOSCOPES, BY KEY PLAYER, 2023 (USD)
  • TABLE 22 AVERAGE SELLING PRICE TREND OF CAPSULE ENDOSCOPES, BY REGION, 2020-2023 (USD PER UNIT)
  • TABLE 23 CASE STUDY 1: INCREASED IMAGING CAPABILITIES FOR PATIENTS WITH SMALL BOWEL ABNORMALITIES
  • TABLE 24 CASE STUDY 2: DETECTION OF GASTRIC POLYP & ERYTHEMA THROUGH MAGNETICALLY CONTROLLED CAPSULE ENDOSCOPES
  • TABLE 25 CASE STUDY 3: AI-ASSISTED CAPSULE ENDOSCOPY TO DETECT OBSCURE GASTROINTESTINAL BLEEDING IN HIGH-RISK CARDIAC PATIENTS
  • TABLE 26 SMART PILLS MARKET: LIST OF KEY PATENTS, JANUARY 2020-DECEMBER 2024
  • TABLE 27 SMART PILLS MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025-DECEMBER 2026
  • TABLE 28 SMART PILLS MARKET: UNMET NEEDS
  • TABLE 29 SMART PILLS MARKET: END-USER EXPECTATIONS
  • TABLE 30 TOP 10 IMPORTERS FOR HSN CODE 901890, BY COUNTRY, 2020-2023 (USD THOUSAND)
  • TABLE 31 TOP 10 EXPORTERS FOR HSN CODE 901890, BY COUNTRY, 2020-2023 (USD THOUSAND)
  • TABLE 32 CASE STUDY 1: CAPSOCAM SV-1 VERSUS PILLCAM SB3 TO DETECT OBSCURE GASTROINTESTINAL BLEEDING
  • TABLE 33 CASE STUDY 2: AARDEX GROUP PARTNERED WITH ETECTRX, INC. TO TRACK MEDICATION-TAKING BEHAVIORS
  • TABLE 34 SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 35 SMART PILLS MARKET FOR SMALL INTESTINE, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 36 SMART PILLS MARKET FOR LARGE INTESTINE, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 37 SMART PILLS MARKET FOR ESOPHAGUS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 38 SMART PILLS MARKET FOR STOMACH, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 39 SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 40 KEY CAPSULE ENDOSCOPES OFFERED BY MAJOR MARKET PLAYERS
  • TABLE 41 SMART PILLS MARKET FOR CAPSULE ENDOSCOPY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 42 KEY PATIENT MONITORING SMART PILLS OFFERED BY MAJOR MARKET PLAYERS
  • TABLE 43 SMART PILLS MARKET FOR PATIENT MONITORING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 44 KEY TARGETED DRUG DELIVERY SMART PILLS UNDER PIPELINE
  • TABLE 45 SMART PILLS MARKET FOR TARGETED DRUG DELIVERY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 46 SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 47 SMART PILLS MARKET FOR OCCULT GASTROINTESTINAL BLEEDING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 48 SMART PILLS MARKET FOR CROHN'S DISEASE, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 49 SMART PILLS MARKET FOR CELIAC DISEASE, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 50 SMART PILLS MARKET FOR SMALL BOWEL TUMORS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 51 SMART PILLS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 52 SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 53 SMART PILLS MARKET FOR HOSPITALS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 54 SMART PILLS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 55 SMART PILLS MARKET FOR OUTPATIENT SETTINGS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 56 SMART PILLS MARKET FOR OTHER END USERS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 57 SMART PILLS MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 58 SMART PILLS MARKET FOR CAPSULE ENDOSCOPY, BY REGION, 2022-2030 (THOUSAND UNITS)
  • TABLE 59 SMART PILLS MARKET FOR PATIENT MONITORING, BY REGION, 2022-2030 (THOUSAND UNITS)
  • TABLE 60 NORTH AMERICA: SMART PILLS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 61 NORTH AMERICA: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 62 NORTH AMERICA: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 63 NORTH AMERICA: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 64 NORTH AMERICA: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 65 US: KEY MACROINDICATORS
  • TABLE 66 US: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 67 US: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 68 US: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 69 US: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 70 CANADA: KEY MACROINDICATORS
  • TABLE 71 CANADA: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 72 CANADA: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 73 CANADA: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 74 CANADA: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 75 EUROPE: SMART PILLS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 76 EUROPE: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 77 EUROPE: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 78 EUROPE: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 79 EUROPE: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 80 GERMANY: KEY MACROINDICATORS
  • TABLE 81 GERMANY: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 82 GERMANY: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 83 GERMANY: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 84 GERMANY: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 85 UK: KEY MACROINDICATORS
  • TABLE 86 UK: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 87 UK: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 88 UK: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 89 UK: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 90 FRANCE: KEY MACROINDICATORS
  • TABLE 91 FRANCE: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 92 FRANCE: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 93 FRANCE: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 94 FRANCE: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 95 ITALY: KEY MACROINDICATORS
  • TABLE 96 ITALY: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 97 ITALY: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 98 ITALY: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 99 ITALY: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 100 SPAIN: KEY MACROINDICATORS
  • TABLE 101 SPAIN: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 102 SPAIN: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 103 SPAIN: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 104 SPAIN: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 105 REST OF EUROPE: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 106 REST OF EUROPE: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 107 REST OF EUROPE: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 108 REST OF EUROPE: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 109 ASIA PACIFIC: SMART PILLS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 111 ASIA PACIFIC: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 114 JAPAN: KEY MACROINDICATORS
  • TABLE 115 JAPAN: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 116 JAPAN: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 117 JAPAN: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 118 JAPAN: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 119 CHINA: KEY MACROINDICATORS
  • TABLE 120 CHINA: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 121 CHINA: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 122 CHINA: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 123 CHINA: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 124 INDIA: KEY MACROINDICATORS
  • TABLE 125 INDIA: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 126 INDIA: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 127 INDIA: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 128 INDIA: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 129 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 130 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 131 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 132 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 133 LATIN AMERICA: SMART PILLS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 134 LATIN AMERICA: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 135 LATIN AMERICA: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 136 LATIN AMERICA: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 137 LATIN AMERICA: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 138 BRAZIL: KEY MACROINDICATORS
  • TABLE 139 BRAZIL: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 140 BRAZIL: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 141 BRAZIL: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 142 BRAZIL: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 143 MEXICO: KEY MACROINDICATORS
  • TABLE 144 MEXICO: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 145 MEXICO: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 146 MEXICO: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 147 MEXICO: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 148 REST OF LATIN AMERICA: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 149 REST OF LATIN AMERICA: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 150 REST OF LATIN AMERICA: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 151 REST OF LATIN AMERICA: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 152 MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 153 MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 154 MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 155 MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 156 MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 157 GCC COUNTRIES: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 158 GCC COUNTRIES: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 159 GCC COUNTRIES: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 160 GCC COUNTRIES: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 161 REST OF MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY TARGET AREA, 2022-2030 (USD MILLION)
  • TABLE 162 REST OF MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 163 REST OF MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY DISEASE INDICATION, 2022-2030 (USD MILLION)
  • TABLE 164 REST OF MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 165 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN SMART PILLS MARKET, JANUARY 2021-JANUARY 2025
  • TABLE 166 SMART PILLS MARKET: DEGREE OF COMPETITION
  • TABLE 167 SMART PILLS MARKET: REGION FOOTPRINT
  • TABLE 168 SMART PILLS MARKET: APPLICATION FOOTPRINT
  • TABLE 169 SMART PILLS MARKET: TARGET AREA FOOTPRINT
  • TABLE 170 SMART PILLS MARKET: DISEASE INDICATION FOOTPRINT
  • TABLE 171 SMART PILLS MARKET: END-USER FOOTPRINT
  • TABLE 172 SMART PILLS MARKET: REGION FOOTPRINT
  • TABLE 173 SMART PILLS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
  • TABLE 174 SMART PILLS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS
  • TABLE 175 SMART PILLS MARKET: PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS, JANUARY 2021-JANUARY 2025
  • TABLE 176 SMART PILLS MARKET: DEALS, JANUARY 2021-JANUARY 2025
  • TABLE 177 SMART PILLS MARKET: OTHER DEVELOPMENTS, JANUARY 2021-JANUARY 2025
  • TABLE 178 MEDTRONIC: COMPANY OVERVIEW
  • TABLE 179 MEDTRONIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 180 MEDTRONIC: PRODUCT APPROVALS & ENHANCEMENTS, JANUARY 2021-JANUARY 2025
  • TABLE 181 MEDTRONIC: DEALS, JANUARY 2021-JANUARY 2025
  • TABLE 182 OLYMPUS CORPORATION: COMPANY OVERVIEW
  • TABLE 183 OLYMPUS CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 184 OLYMPUS CORPORATION: OTHER DEVELOPMENTS, JANUARY 2021-JANUARY 2025
  • TABLE 185 CAPSOVISION, INC.: COMPANY OVERVIEW
  • TABLE 186 CAPSOVISION, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 187 CAPSOVISION, INC.: PRODUCT APPROVALS & ENHANCEMENTS, JANUARY 2021-JANUARY 2025
  • TABLE 188 INTROMEDIC: COMPANY OVERVIEW
  • TABLE 189 INTROMEDIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 190 JINSHAN SCIENCE & TECHNOLOGY: COMPANY OVERVIEW
  • TABLE 191 JINSHAN SCIENCE & TECHNOLOGY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 192 ANX ROBOTICS: COMPANY OVERVIEW
  • TABLE 193 ANX ROBOTICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 194 ANX ROBOTICS: PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS, JANUARY 2021-JANUARY 2025
  • TABLE 195 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW
  • TABLE 196 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.: PRODUCTS/SERVICES/ SOLUTIONS OFFERED
  • TABLE 197 ETECTRX: COMPANY OVERVIEW
  • TABLE 198 ETECTRX: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 199 ETECTRX: PRODUCT ENHANCEMENTS, JANUARY 2021-JANUARY 2025
  • TABLE 200 ETECTRX: DEALS, JANUARY 2021-JANUARY 2025
  • TABLE 201 BODYCAP: COMPANY OVERVIEW
  • TABLE 202 BODYCAP: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 203 BODYCAP: PRODUCT LAUNCHES, JANUARY 2021-JANUARY 2025
  • TABLE 204 BODYCAP: DEALS, JANUARY 2021-JANUARY 2025
  • TABLE 205 CHECK-CAP: COMPANY OVERVIEW
  • TABLE 206 CHECK-CAP: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 207 CHECK-CAP: PRODUCT APPROVALS, JANUARY 2021-JANUARY 2025
  • TABLE 208 CHECK-CAP: EXPANSIONS, JANUARY 2021-JANUARY 2025
  • TABLE 209 SHANGXIAN MINIMAL INVASIVE INC.: COMPANY OVERVIEW
  • TABLE 210 SHANGXIAN MINIMAL INVASIVE INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 211 VELOCE CORPORATION: COMPANY OVERVIEW
  • TABLE 212 BIOCAM: COMPANY OVERVIEW
  • TABLE 213 ENDIATX: COMPANY OVERVIEW
  • TABLE 214 RF CO., LTD.: COMPANY OVERVIEW
  • TABLE 215 CELERO SYSTEMS: COMPANY OVERVIEW
  • TABLE 216 BIORA THERAPEUTICS, INC.: COMPANY OVERVIEW
  • TABLE 217 INNURVATION: COMPANY OVERVIEW
  • TABLE 218 RANI THERAPEUTICS: COMPANY OVERVIEW
  • TABLE 219 MOTILIS MEDICA SA: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 SMART PILLS MARKET SEGMENTATION & GEOGRAPHICAL SPREAD
  • FIGURE 2 SMART PILLS MARKET: YEARS CONSIDERED
  • FIGURE 3 SMART PILLS MARKET: RESEARCH DESIGN
  • FIGURE 4 SMART PILLS MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 5 SMART PILLS MARKET: KEY PRIMARY SOURCES
  • FIGURE 6 SMART PILLS MARKET: KEY DATA FROM PRIMARY SOURCES
  • FIGURE 7 SMART PILLS MARKET: INSIGHTS FROM KEY PRIMARIES
  • FIGURE 8 BREAKDOWN OF PRIMARY EXPERTS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 9 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
  • FIGURE 10 SMART PILLS MARKET: BOTTOM-UP APPROACH (DEMAND-SIDE ANALYSIS)
  • FIGURE 11 SMART PILLS MARKET: TOP-DOWN APPROACH
  • FIGURE 12 SMART PILLS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024-2030)
  • FIGURE 13 SMART PILLS MARKET: CAGR PROJECTIONS (SUPPLY SIDE)
  • FIGURE 14 SMART PILLS MARKET: DATA TRIANGULATION
  • FIGURE 15 SMART PILLS MARKET, BY APPLICATION, 2024 VS. 2030 (USD MILLION)
  • FIGURE 16 SMART PILLS MARKET, BY TARGET AREA, 2024 VS. 2030 (USD MILLION)
  • FIGURE 17 SMART PILLS MARKET, BY DISEASE INDICATION, 2024 VS. 2030 (USD MILLION)
  • FIGURE 18 SMART PILLS MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)
  • FIGURE 19 REGIONAL SNAPSHOT OF SMART PILLS MARKET
  • FIGURE 20 INCREASING ADOPTION OF CAPSULE ENDOSCOPY IN EMERGING ECONOMIES TO FUEL UPTAKE OF SMART PILLS
  • FIGURE 21 US AND CAPSULE ENDOSCOPY SEGMENTS DOMINATED NORTH AMERICAN SMART PILLS MARKET IN 2023
  • FIGURE 22 CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2024 TO 2030
  • FIGURE 23 ASIA PACIFIC TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 24 EMERGING MARKETS TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD
  • FIGURE 25 SMART PILLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 26 HEALTHCARE SECURITY BREACHES OF 500 + RECORDS, 2009-2024
  • FIGURE 27 SMART PILLS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
  • FIGURE 28 SMART PILLS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 29 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY APPLICATION
  • FIGURE 30 KEY BUYING CRITERIA FOR SMART PILLS, BY APPLICATION
  • FIGURE 31 SMART PILLS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 32 SMART PILLS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 33 AVERAGE SELLING PRICE OF SMART PILLS, BY KEY PLAYER (2023)
  • FIGURE 34 SMART PILLS MARKET: GLOBAL PATENT PUBLICATION TRENDS (2015-2024)
  • FIGURE 35 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR SMART PILL PATENTS (JANUARY 2014-DECEMBER 2024)
  • FIGURE 36 TOP APPLICANTS FOR SMART PILL PATENTS (COUNTRY/REGION) (JANUARY 2014-DECEMBER 2024)
  • FIGURE 37 SMART PILLS MARKET: FUNDING AND NUMBER OF DEALS (2020-2024)
  • FIGURE 38 MARKET POTENTIAL OF AI/GEN AI ON SMART PILLS ACROSS INDUSTRIES
  • FIGURE 39 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
  • FIGURE 40 NORTH AMERICA: SMART PILLS MARKET SNAPSHOT
  • FIGURE 41 ASIA PACIFIC: SMART PILLS MARKET SNAPSHOT
  • FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS IN SMART PILLS MARKET, 2019-2023 (USD MILLION)
  • FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS IN SMART PILLS MARKET (2023)
  • FIGURE 44 SMART PILLS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 45 SMART PILLS MARKET: COMPANY FOOTPRINT
  • FIGURE 46 SMART PILLS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 47 EV/EBITDA OF KEY VENDORS
  • FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 49 SMART PILLS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 50 MEDTRONIC: COMPANY SNAPSHOT
  • FIGURE 51 OLYMPUS CORPORATION: COMPANY SNAPSHOT